Thermo Fisher Scientific Inc (TMO)
Quick ratio
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 9,852,000 | 1,982,000 | 4,579,000 | 4,134,000 | 4,009,000 | 4,645,000 | 7,084,000 | 5,506,000 | 8,077,000 | 6,151,000 | 3,133,000 | 3,482,000 | 8,524,000 | 2,919,000 | 1,888,000 | 2,752,000 | 4,477,000 | 12,027,000 | 7,023,000 | 5,583,000 |
| Short-term investments | US$ in thousands | 253,000 | 1,564,000 | 1,814,000 | 1,813,000 | 1,561,000 | 2,000,000 | 1,750,000 | 1,751,000 | 3,000 | — | — | — | 2,000 | 22,000 | 5,000 | 150,000 | — | — | 65,000 | 121,000 |
| Receivables | US$ in thousands | 8,900,000 | 8,911,000 | 10,035,000 | 9,821,000 | 9,626,000 | 9,796,000 | 9,430,000 | 9,353,000 | 9,664,000 | 9,835,000 | 9,486,000 | 9,297,000 | 9,427,000 | 8,919,000 | 8,892,000 | 8,953,000 | 8,945,000 | 6,365,000 | 6,280,000 | 6,337,000 |
| Total current liabilities | US$ in thousands | 15,189,000 | 14,888,000 | 12,718,000 | 13,174,000 | 13,332,000 | 14,601,000 | 14,772,000 | 13,937,000 | 14,012,000 | 14,158,000 | 14,112,000 | 15,884,000 | 17,010,000 | 11,118,000 | 10,997,000 | 12,070,000 | 13,436,000 | 7,753,000 | 6,925,000 | 6,995,000 |
| Quick ratio | 1.25 | 0.84 | 1.29 | 1.20 | 1.14 | 1.13 | 1.24 | 1.19 | 1.27 | 1.13 | 0.89 | 0.80 | 1.06 | 1.07 | 0.98 | 0.98 | 1.00 | 2.37 | 1.93 | 1.72 |
December 31, 2025 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($9,852,000K
+ $253,000K
+ $8,900,000K)
÷ $15,189,000K
= 1.25
Peer comparison
Dec 31, 2025
Company name
Symbol
Quick ratio
Thermo Fisher Scientific Inc
TMO
1.25
Agilent Technologies Inc
A
1.40
Danaher Corporation
DHR
1.25